Introduction Although tumor necrosis factor inhibitors (TNFi) might be expected to protect against nonalcoholic fatty liver disease (NAFLD), we have seen patients who appeared to develop NAFLD during TNFi treatment. We aimed to explore risk factors for this TNFi complication in a case-control study. Methods We reviewed clinic records at our VA hospital to identify patients with inflammatory diseases who developed aminotransferase elevations during TNFi therapy and who had liver biopsies showing NAFLD. These patients were matched with patients in each of three control groups: (i) inflammatory disease controls: patients on TNFi treatment with normal aminotransferase levels, (ii) nonalcoholic steatohepatitis (NASH) controls: patients with biopsy-proven NASH with no other inflammatory disease, and (iii) healthy controls. Genotyping was performed for PNPLA3, a gene predisposing to NASH. Results We identified eight cases (five steatohepatitis, three steatosis); elevated aminotransferase levels were first observed 1-63 months into TNFi therapy (average 12 months). TNFi therapy was stopped in five patients, whose aminotransferase levels then normalized within 2-8 months. There were no significant differences between cases and inflammatory disease controls in the frequency of features of metabolic syndrome. Cases had more methotrexate exposure than inflammatory controls (50 vs. 12.5%, P = 0.28). PNPLA3 genotyping revealed mutations in 75% of cases, 38% of inflammatory controls, 88% of NASH controls, and 63% of healthy controls (P = NS). Conclusion Our findings suggest that NAFLD can be a side effect of TNFi therapy, and that methotrexate exposure and PNPLA3 gene mutations might be risk factors. Further studies are needed to determine how TNFi causes NAFLD and to confirm these risk factors. Eur
Introduction
Nonalcoholic fatty liver disease (NAFLD) spans a spectrum of liver injuries ranging from simple hepatic steatosis to nonalcoholic steatohepatitis (NASH) with cirrhosis. NAFLD is now the most common chronic liver disease in the USA. In the Dallas Heart Study, almost one-third of patients were found to have NAFLD [1] . Severe obesity and the metabolic syndrome (a disorder of energy storage and utilization characterized by central obesity, hypertriglyceridemia, low high-density lipoprotein levels, elevated fasting glucose levels, and high blood pressure) are strongly associated with NAFLD [2, 3] . Up to 90% [4] of severely obese adults and 70% [5] of adults with diabetes have NAFLD. Fortunately, most patients with NAFLD have an excellent prognosis, and only a minority develop NASH that progresses to cirrhosis, liver failure, and/or liver cancer. The metabolic syndrome is an important risk factor for NASH in patients with NAFLD [6] .
Metabolic syndrome has also been associated with the activity of a number of immune-mediated inflammatory diseases, such as rheumatoid arthritis [7, 8] , psoriasis, psoriatic arthritis [9, 10] , and ankylosing spondylitis [11] . Even in inflammatory bowel diseases that were historically associated with cachexia, recent studies have shown a high prevalence of obesity and metabolic syndrome, comparable to that in the general population [12] . All of these inflammatory disorders are associated with overexpression of the proinflammatory cytokine tumor necrosis factor α (TNFα), and the disorders respond to treatment with TNF inhibitors (TNFi) . TNFα also appears to be a key mediator of fatty liver disease and hepatic fibrosis [13] , and TNFα has been proposed as a potential therapeutic target for patients with NASH. Although these data suggest that TNFi treatment might prevent NAFLD, we have observed a number of patients with immune-mediated inflammatory diseases to develop NAFLD during treatment with TNFi, which resolved when TNFi therapy was stopped. In this case-control study, we have explored potential risk factors for the development of NAFLD during TNFi therapy.
Methods
We reviewed the medical records of patients seen at our inflammatory bowel disease and rheumatology clinics to identify those who developed abnormal alanine aminotransferase (ALT) levels during TNFi therapy and whose liver biopsies showed NAFLD (NASH or steatosis). We also identified three control groups: (i) inflammatory disease controls: patients on TNFi treatment with normal ALT levels, matched to patients on the basis of the type of underlying inflammatory disease, race, sex, age, and BMI, (ii) NASH controls: patients with biopsy-proven NASH who had no other apparent inflammatory disease, matched to cases on the basis of race, and (iii) healthy controls: patients without diabetes or liver disease who were recruited (and matched for race and sex to our cases) from among healthy veterans undergoing screening colonoscopy and among healthy medical staff members at our VA hospital. Patients meeting the study inclusion criteria were invited to participate, and informed consent was obtained. Patients were recruited for participation between April 2013 and April 2014. Data on demographics, lipid panels, and clinical features of metabolic syndrome were obtained for all patients. Patients were considered to be alcohol users if they consumed at least one alcoholic drink per day. For methotrexate users, total cumulative exposure was considered significant if they received a total dose of 3 g or more.
Liver biopsies of the patients and the controls with NASH were reviewed by a single expert pathologist (T.C.) in conjunction with an expert hepatologist (G.B.). Only six of the NASH controls were available for review. Biopsies were reviewed using Brunt's criteria and the NASH Clinical Research Network pathologic criteria for the diagnosis of NASH [14, 15] .
For each patient and matched control, genotyping was performed for PNPLA3, a polymorphism known to confer susceptibility to NAFLD [7] , using a specific 5′-nucleotidase assay for the rs738409 single-nucleotide polymorphism of PNPLA3 (rs738409[G], encoding I148M; Life Technologies). The single-nucleotide polymorphism assay was performed on an HT7900 Real-Time PCR system, using TaqMan reagents (Life Technologies, Grand Island, New York, USA).
Statistical analysis
Analyses were carried out using Fisher's exact test for categorical variables and the unpaired t-test (normally distributed) or the Mann-Whitney test (not normally distributed) for continuous variables. For comparison of multiple groups, analysis of variance was used. Statistical analysis was carried out using GraphPad Instat 3 (GraphPad Software, La Jolla, California, USA).
All authors had access to the study data and reviewed and approved the final manuscript. The institutional review board of Dallas VA Medical Center approved this study.
Results
Cases and inflammatory controls were predominantly middle-aged, obese men with features of metabolic syndrome
We enrolled eight cases (patients with inflammatory diseases who developed abnormal ALT levels during TNFi treatment and whose liver biopsies revealed NAFLD), whom we matched with eight inflammatory controls (inflammatory disease patients who did not develop liver disease during TNFi therapy) on the basis of the type of underlying inflammatory disease, race, sex, age, and BMI. All of the cases and matched inflammatory disease controls were men. There were no significant differences between cases and inflammatory disease controls in any baseline characteristic including the frequencies of weight gain during treatment, the presence of diabetes mellitus type 2, alcohol use, and hypertriglyceridemia (Table 1) . Methotrexate use (50 vs. 12.5%) and hypertension (63 vs. 38%) were more common among the cases than among the inflammatory disease controls, but these differences were not statistically significant ( Table 1) .
The cases included patients with Crohn's disease, rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis who were treated with either infliximab, adalimumab, or etanercept ( Table 2) . Interestingly, 50% of the cases were of Hispanic background, whereas the rest were nonHispanic Whites. Of note, abnormal liver enzyme levels during TNFi treatment were not observed in any African-American patient. The average peak ALT was 111 (range 69-180) and the peak AST was 63 (range 38-88). In the majority of cases, bilirubin and alkaline phosphatase levels remained normal. The time to the development of abnormal liver tests after starting TNFi therapy ranged from 1 to 63 months, with an average of 12 months. Three patients elected not to stop the therapy; among those who did stop the therapy, the liver tests normalized within 2-8 months (average 6 months). An illustrative case with the time course of drug exposure and aminotransferase levels is shown in Fig. 1 . In this case, aminotransferase levels showed an increase 6 months after the initiation of infliximab therapy, with rapid improvement when infliximab was stopped. When treatment was started with another TNFi, adalimumab, aminotransferase levels rapidly increased. When this second TNFi was stopped, aminotransferase levels declined slowly.
Liver histology
Liver biopsy revealed NASH in five cases (four with portal fibrosis and one with cirrhosis) and steatosis in three cases (one with portal fibrosis and two with no fibrosis; Fig. 2 and Table 3 ). Only the NASH controls (six of eight) had liver biopsies available for comparison with the cases. Cases and NASH controls showed different patterns of hepatic steatosis; four of eight cases showed sparing of steatosis around the central vein (zone 3), whereas the NASH controls showed a more uniform distribution of steatosis. Of note, the majority of cases (88%) and controls (66%) had only minimal hepatic inflammation. In addition, the majority of cases (88%) and NASH controls (84%) had either zone 3 fibrosis and portal fibrosis or portal fibrosis alone (Table 3) . Interestingly, granulomas were seen in 75% of the cases but in none of the NASH controls.
Genotyping
Genotyping for I148M PNPLA3 revealed mutations in one or both alleles in 75% of cases, compared with only 38% of inflammatory controls who also received TNFi therapy but did not have liver function test abnormalities (P =0.31). Interestingly, 88% of patients with NASH had mutations in one or both alleles, whereas 63% of healthy, race-matched (50% of Hispanic origin) controls had mutations in one or both alleles ( Fig. 3 ).
Discussion
TNFi therapy is widely used to treat immune-mediated diseases like rheumatoid arthritis and inflammatory bowel disease, and one might expect this therapy to have beneficial effects against NAFLD. However, we describe a series of eight patients who developed features of NAFLD during TNFi therapy, most of whom had not gained weight and whose ALT levels normalized when TNFi treatment was stopped. Of note, three patients elected to continue TNFi therapy after risk-benefit discussions: two had no further increase in transaminase levels, and transaminase levels normalized in the third case. Earlier reports of patients who developed abnormal liver test results during TNFi therapy have described liver biopsies showing features of autoimmune hepatitis [16] [17] [18] or drug-induced liver injury [19] . However, none of our cases had biopsies typical of autoimmune hepatitis or drug-induced liver injury. More recent reports have demonstrated NAFLD in patients on TNFi therapy. In a case series of seven patients with Crohn's disease and elevated liver enzyme levels (six of whom were on biologics or immunomodulators), liver biopsies showed NAFLD in all seven patients [20] . However, six of the seven patients in the study had gained weight, the temporal relationship between the transaminase rise and the start of biologic therapy was unclear, and the authors attributed NAFLD to weight gain. In another study of 48 patients with psoriatic arthritis who had hepatic steatosis before TNFi treatment, hepatic steatosis worsened in patients whose arthritis symptoms persisted during TNFi treatment, whereas it remained unchanged in those whose arthritis symptoms responded to TNFi therapy [21] . Our study differs substantially from these two investigations in at least two important ways. First, all our cases had normal aminotransferase levels documented before the start of TNFi therapy, and all aminotransferase elevations occurred during TNFi therapy. Second, we included three pertinent control groups to better understand the etiology of this seemingly paradoxical TNFi effect.
Our three control groups (matched to our cases) included patients with similar inflammatory diseases who were treated with TNFi but did not develop abnormal transaminase levels, patients who had biopsy-proven NASH without other inflammatory diseases, and healthy controls with no known inflammatory disease or liver disease. There were no significant differences in the frequency of risk factors for metabolic syndrome between our cases and the control patients on TNFi who did not develop liver abnormalities. However, exposure to methotrexate was more common among cases than among inflammatory disease controls (50 vs. 12.5%, P-value not significant). Methotrexate liver injury can mimic NAFLD and might have contributed to the ALT elevations in our cases. We also found more PNPLA3 polymorphism I148M (a DNA sequence variation strongly associated with increased hepatic fat levels and hepatic inflammation) in our cases than in inflammatory disease controls on TNFi who did not develop liver abnormalities. PNPLA3 polymorphism I148M has emerged as the key genetic determinant of NAFLD, with a recent systematic review confirming its strong association with increased hepatic fat content and increased risk for elevated serum alanine aminotransferase levels, NASH, and fibrosis, irrespective of alcohol consumption, BMI, and diabetes [22] . The I148M PNPLA3 allele is most common in Hispanics (49% in Hispanics compared with 23% in Whites and 17% in Blacks), the group most susceptible to NAFLD [23] . It is also interesting to note that, in our study, four of eight of our cases were Hispanics, whereas Hispanics comprise only a small minority of our patient population.
The mechanisms underlying the development of NAFLD in patients receiving TNFi therapy are not clear. Indeed, our findings are particularly surprising in light of reports that have documented elevated serum TNFα levels and hepatic TNFα messenger RNA (mRNA) expression in patients with NASH [24, 25] . In a mouse model of NASH, treatment with anti-TNFα antibodies improved liver histology, reduced hepatic total fatty acid content, and decreased serum ALT levels [26] . Moreover, studies on the use of pentoxifylline, which inhibits the production of TNFα, as a treatment for NASH have noted some improvement in aminotransferase levels [27, 28] .
The development and progression of NASH are multifactorial processes, and NASH may evolve through varying pathways depending upon the immunological milieu or environment [29] . The liver histopathological findings in the majority of our cases were consistent with early NASH, as evidenced by sparing of steatosis around the central vein in one-half of the cases [30] . It is also interesting to note that we found granulomas in 75% of our cases but in none of the NASH controls, even though granulomas can often be found in the liver of patients with rheumatologic disorders. Although their presence may be the consequence of having a rheumatologic disorder, the importance of these granulomas as a marker or potential modular of NASH in patients with autoimmune diseases treated with TNFi therapy is not clear. Our study has several major strengths. First, our cases were reviewed by a multidisciplinary group including a gastroenterologist, a hepatologist, a rheumatologist, and a pathologist. Second, we utilized liver histology rather than less specific imaging techniques to document NAFLD. Third, we were able to evaluate all of our cases and controls for polymorphisms in the PNPLA3 gene. Limitations of our study include the small sample size and the retrospective nature of data collection. We did not have uniform documentation of inflammatory disease activity at the time of peak ALT levels, and thus were unable to clearly define the contribution of inflammatory disease activity to liver abnormalities. Another limitation is that liver biopsy was not repeated to document resolution of the NAFLD when TNFi therapy was discontinued. Moreover, our cases were all male and the findings may not be applicable to female individuals. Nevertheless, our findings are relevant as elevation in aminotransferase levels during TNFi therapy might warrant consideration of stopping TNFi therapy in patients who have disabling inflammatory disease symptoms. Moreover, awareness of potential risk factors for the development of NAFLD during TNFi therapy might identify patients who warrant especially close monitoring of aminotransferase levels.
Conclusion
In our case series of patients with immune-mediated diseases receiving TNFi therapy who developed elevations in ALT levels, we found that NAFLD/NASH were the common findings on liver biopsies. However, the mechanisms underlying this association remain incompletely understood. On the basis of our data, potential risk factors for ALT elevation during TNFi therapy include concurrent methotrexate use, Hispanic race, and a predisposing Table 2 . polymorphism of the PNPLA3 gene. Clearly, further studies are warranted to identify the underlying mechanisms and to confirm these risk factors. 
